Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
Around 30% to 40% of people with diffuse large B-cell lymphoma (DLBCL) experience a relapse after remission, and 83% of those who relapse have symptoms. Relapse symptoms can be the same as those that ...
Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically ...
"We found that older age, early relapse, and noncurative treatments were significantly associated with inferior outcomes at a population level." — Inna Y. Gong, MD, PhD, hematologist in the Division ...
Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of large B-lymphocytes that accounts for 25–30% of B-cell non-Hodgkin lymphomas. It is the most common lymphoma subtype in western countries and ...
SurvivorNet on MSN
For high-risk lymphoma, adding targeted drugs tafasitamab and lenalidomide to standard treatment keeps cancer away for longer
The frontMIND study adds two immune‑based medicines (tafasitamab and lenalidomide) to standard R‑CHOP, a type of chemotherapy, which helped patients stay in remission longer, reducing the risk of the ...
Lymph nodes are key control centers in the immune system and play an important role in defending the body against infections and tumors. For these processes to function properly, immune cells (B cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results